11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.
Sunitinib is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties used for treatment of renal cell carcinoma and gastrointestinal stromal tumors at a dose of 50 mg/day consecutively for 4 weeks followed by 2 weeks off per cycle. At present, no data are available on the early prediction of sunitinib response in renal cell carcinoma. We report a clinical case of a patient with metastatic renal cell carcinoma diagnosed with 11C-acetate PET and conventional CT and treated with sunitinib. Partial and complete remission documented by CT was preceded by early functional tumor inhibition shown by 11C-acetate-PET after only 14 days of therapy. This case report highlights some interesting points related to the potential role of a novel non-FDG PET tracer, 11C-acetate, in the early prediction of the response to targeted therapies in metastatic renal cell carcinoma.
Maleddu
Alessandra
A
Institute of Hematology and Medical Oncology "L. & A. Seragnoli", Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. alessandramaleddu@gmail.com
Pantaleo
Maria A
MA
Castellucci
Paolo
P
Astorino
Maria
M
Nanni
Cristina
C
Nannini
Margherita
M
Busato
Fiorenza
F
Di Battista
Monica
M
Farsad
Mohsen
M
Lodi
Filippo
F
Boschi
Stefano
S
Fanti
Stefano
S
Biasco
Guido
G
D000310:Adrenal Gland Neoplasms / Q000556:secondary / Q000601:surgery; D000315:Adrenalectomy; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002250:Carbon Radioisotopes; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology* / Q000601:surgery; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D009392:Nephrectomy; D010190:Pancreatic Neoplasms / Q000556:secondary / Q000601:surgery; D016577:Pancreaticoduodenectomy; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D002250:Carbon Radioisotopes; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D019788:Fluorodeoxyglucose F18; D000077210:Sunitinib